[Other] Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials |
Reward10points
|
| |
20
Graphitic Nanoporous Carbon Thin Films: Fabrication Method, Structural, Electrical and Gas Sensor Properties
20
Stacking-dependent topological magnons in bilayer CrI3
20
Safety and Efficacy of Gemcitabine Plus Cisplatin Against Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective Study
10
Combinatorial strategies to target RAS-driven cancers
10
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity
